A Study for Assessing the Safety of Hanita Glaucoma Shunt in Glaucoma Patients

NCT ID: NCT04796883

Last Updated: 2022-03-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-06-30
• Study Completion Date: 2021-11-15

Brief Summary

The HANITA Glaucoma Filtration Device is intended to reduce intraocular pressure in glaucoma patients where medical and conventional surgical treatments have failed.

Detailed Description

Study Design:

This study is a prospective, single-arm single-center, open-label study.

Study population:

Men and women diagnosed with open-angle glaucoma who require glaucoma surgery procedures that meet the inclusion/exclusion criteria and provide written informed consent will be enrolled in the study.

Enrollment:

A total of 30 subjects will be enrolled:

15 patients will be implanted according to procedure 1 (see section 8.7), at completion additional 15 patients will be implanted according to procedure 2 (see section 8.7)

Investigational sites:

One (1) center will participate in this study.

Duration of Subject participation:

Completion of active enrolment is anticipated to last approximately 6 months. The primary endpoint will be achieved when the final study subject has completed 6 months follow-up.

Study Group:

A single study group. This is a single-arm design; there is no control device in this study.

Visits & Procedures Pre-operative visit: 0-3 months prior to the implantation procedure. The visit will include the subject's qualification assessment for inclusion/exclusion criteria as described above. Informed consent must be signed.

Complete anamnesis will be taken including the subject's medical complaints, medical history, and medication use. Ophthalmic examinations as well as ultrasound biomicroscopy.

Surgical procedure: Procedure will be performed under anesthesia (at physician discretion) and a Hanita shunt will be implanted.

Follow-up: All subjects will have regular follow-up visits at 1 and 7 days and on 1, 3, and 6 months post-implantation. 1-year post-operative evaluation is optional at the sponsor's discretion. All postoperative visits will include a complete ophthalmic examination,

Conditions

Glaucoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

single arm

Hanita Glaucoma shunt Ver.3.2

Group Type: EXPERIMENTAL

Hanita Glaucoma shunt Ver.3.2

Intervention Type: DEVICE

The procedure will be performed under anesthesia (at physician discretion) and a Hanita shunt devce will be implanted.

Interventions

Hanita Glaucoma shunt Ver.3.2

The procedure will be performed under anesthesia (at physician discretion) and a Hanita shunt devce will be implanted.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Subject is between 40 and 80 years of age
• Subject diagnosed with primary Open-angle glaucoma
• Subject is Diagnosed with glaucoma uncontrolled by medical therapy which meets at least one of the following criteria:
• Failed one or more incisional intraocular glaucoma surgeries (e.g., glaucoma filtering surgery or tube shunt)
• Failed one or more cilioablative procedures (e.g., cryotherapy, cyclodiode therapy)
• Have any other condition (e.g., conjunctival scarring, uveitis) in which a conventional incisional glaucoma surgery like trabeculectomy would be more likely to fail than for a person with uncomplicated primary open-angle glaucoma
• Under present-day criteria subject is a candidate for glaucoma surgery
• Intraocular pressures of the eye above or equal to 25 mmHg with or without medication
• The angle should be grade 3 in at least the 180º superior and not less than grade 2 at any level of the angle
• Subject understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed

• The subject has best-corrected visual acuity (BCVA) worse than 20/200 in the non-study eye
• Subject consumes the anti aggregating or anticoagulant and cannot suspend the use at least four days prior to the procedure, and antiplatelet drugs one week before
• The subject is diagnosed with glaucoma-related to other comorbidities (especially neovascular glaucoma, inflammatory glaucomas, glaucomas associated with hemorrhages and pseudoexfoliation)
• Subject with inadequate space in the anterior chamber and/or angle as determined by slit-lamp examination and gonioscopy
• The subject is diagnosed with active anterior segment intraocular inflammation
• The subject is obligated to previous participation in another study with any investigational drug or device within the past 30 days
• Subject is pregnant

Exclusion Criteria

• Subject diagnosed with primary angle-closure glaucoma (PACG)
• Subject diagnosed with normal-tension glaucoma (NTG)
• Subject diagnosed with secondary glaucoma
• Subject diagnosed with neovascular glaucoma
• Patient eyes with no light perception vision
• Patient eyes with the need for a combined glaucoma procedure or anticipated need for additional ocular surgery or retinal laser procedure within the 6-month follow-up period

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hanita Lenses

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

VISSUM

Madrid, , Spain

Countries

Spain

Other Identifiers

HGS-01

Identifier Type: -

Identifier Source: org_study_id